Advertisement
ARRY vs ETON
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARRY is a Buy and ETON is a Hold.
| ARRY | ETON | ARRY / ETON | |
| Capitalization | 679M | 1.65B | 41% |
| EBITDA | 7.25M | 20.9M | 35% |
| Gain YTD | -52.169 | 240.745 | -22% |
| P/E Ratio | 56.91 | 147.74 | 39% |
| Revenue | 1.19B | 106M | 1,118% |
| Total Cash | 307M | 26.8M | 1,146% |
| Total Debt | 753M | 29M | 2,597% |
ARRY | ETON | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 4 | 89 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 99 Overvalued | 78 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 1 | |
SMR RATING 1..100 | 100 | 29 | |
PRICE GROWTH RATING 1..100 | 84 | 34 | |
P/E GROWTH RATING 1..100 | 24 | 43 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ETON's Valuation (78) in the Pharmaceuticals Major industry is in the same range as ARRY (99) in the Biotechnology industry. This means that ETON’s stock grew similarly to ARRY’s over the last 12 months.
ETON's Profit vs Risk Rating (1) in the Pharmaceuticals Major industry is significantly better than the same rating for ARRY (100) in the Biotechnology industry. This means that ETON’s stock grew significantly faster than ARRY’s over the last 12 months.
ETON's SMR Rating (29) in the Pharmaceuticals Major industry is significantly better than the same rating for ARRY (100) in the Biotechnology industry. This means that ETON’s stock grew significantly faster than ARRY’s over the last 12 months.
ETON's Price Growth Rating (34) in the Pharmaceuticals Major industry is somewhat better than the same rating for ARRY (84) in the Biotechnology industry. This means that ETON’s stock grew somewhat faster than ARRY’s over the last 12 months.
ARRY's P/E Growth Rating (24) in the Biotechnology industry is in the same range as ETON (43) in the Pharmaceuticals Major industry. This means that ARRY’s stock grew similarly to ETON’s over the last 12 months.
| ARRY | ETON | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 80% | 1 day ago 82% |
| Stochastic ODDS (%) | 1 day ago 81% | 1 day ago 83% |
| Momentum ODDS (%) | 1 day ago 84% | 1 day ago 83% |
| MACD ODDS (%) | 1 day ago 90% | 1 day ago 88% |
| TrendWeek ODDS (%) | 1 day ago 87% | 1 day ago 78% |
| TrendMonth ODDS (%) | 1 day ago 85% | 1 day ago 83% |
| Advances ODDS (%) | 5 days ago 79% | 23 days ago 84% |
| Declines ODDS (%) | 15 days ago 88% | 5 days ago 78% |
| BollingerBands ODDS (%) | N/A | 1 day ago 76% |
| Aroon ODDS (%) | 1 day ago 81% | 1 day ago 81% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ARRY’s FA Score shows that 1 FA rating(s) are green while ETON’s FA Score has 2 green FA rating(s).
- ARRY’s FA Score: 1 green, 4 red.
- ETON’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ARRY’s TA Score shows that 4 TA indicator(s) are bullish while ETON’s TA Score has 3 bullish TA indicator(s).
- ARRY’s TA Score: 4 bullish, 3 bearish.
- ETON’s TA Score: 3 bullish, 5 bearish.
Price Growth
ARRY (@Alternative Power Generation) experienced а -4.13% price change this week, while ETON (@Pharmaceuticals: Generic) price change was -1.42% for the same time period.
The average weekly price growth across all stocks in the @Alternative Power Generation industry was -5.54%. For the same industry, the average monthly price growth was -15.12%, and the average quarterly price growth was -36.58%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -4.68%. For the same industry, the average monthly price growth was -3.54%, and the average quarterly price growth was +33.30%.
Reported Earning Dates
ARRY is expected to report earnings on Nov 05, 2026.
ETON is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Alternative Power Generation (-5.54% weekly)The alternative power generation industry consists of companies that operate power facilities converting non-conventional forms of energy into electricity. These energy forms are alternatives to fossil fuels, and many of them are derived from natural resources. Alternative energy forms include solar, wind, hydro, and geothermal steam. A major purpose behind using alternative energy – also called ‘clean’ energy - is to address concerns related to the more conventional fossil fuels, such as the latter’s high carbon dioxide emissions which is often considered a factor in global warming. Alternative power generation has been gaining traction in recent years, and could grow further in the future. Large organizations like Google have invested substantially in wind and solar energy-powered electricity. Some of the prominent U.S. companies operating in the alternative power generation industry includes Ormat Technologies, Inc., TerraForm Power, Inc. and NextEra Energy Partners LP.
@Pharmaceuticals: Generic (-4.68% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement